life Article Aerobic Capacity in Adults with Congenital Heart Disease: More than VO2peak, a Follow-Up Study Kelly Ferri 1, *, Ignasi Gich 2 , Myriam Guerra-Balic 1 , Guillermo R. Oviedo 1 , Maite Doñate 3 , Mireia Parra 3 , Bàrbara Carbonell-Prat 4 , Laura Dos-Subirá 4 and Ricard Serra-Grima 3 1 FPCEE—Blanquerna, Ramon Llull University, 08022 Barcelona, Spain 2 CIBER Epidemiology and Public Health (CIBERESP), 08025 Barcelona, Spain 3 Cardiology Department, Santa Creu i Sant Pau Hospital, IIB Sant Pau, 08025 Barcelona, Spain 4 Adult Congenital Heart Disease Unit, Vall d’Hebron University Hospital, 08035 Barcelona, Spain * Correspondence: kellyprisciladf@blanquerna.url.edu Abstract: To control the development of people with congenital heart disease (CHD), it is important to follow their aerobic capacity (AC), especially when they exercise. This research aimed to study the progress of AC during a follow-up of adults with CHD. This is a longitudinal study which involved 127 adults with a mean age of 33.8 (11.1) years (57.5% female; 75 moderate CHD and 52 complex CHD) who had undergone two cardiopulmonary exercise tests (CEPT) in at least one year between the first and the second test. The AC and exercise performance (EP) (duration of exercise time, velocity and per- centage of grade) were assessed using a ramp protocol over a treadmill. In a mean of 4.5 (2.0) years of follow-up, there was a significant decrease in AC. The VO2peak at baseline was 27.8 (27.7) mL/kg/min (82.9% (20.3%) predicted) versus 26.6 (7.8) mL/kg/min (79.3% (20.8%) predicted) at the end of follow-up. This decline was independent of the body weight increase. There was no significant difference in HRpeak and EP among periods. These results suggest a sign of favorable evolution Citation: Ferri, K.; Gich, I.; of adults with CHD. More research is needed to study different factors that could contribute to Guerra-Balic, M.; Oviedo, G.R.; AC reduction. Doñate, M.; Parra, M.; Carbonell-Prat, B.; Dos-Subirá, L.; Serra-Grima, R. Keywords: congenital heart disease; aerobic capacity; follow-up; adults Aerobic Capacity in Adults with Congenital Heart Disease: More than VO2peak , a Follow-Up Study. Life 2022, 12, 2118. https://doi.org/10.3390/ life12122118 1. Introduction Evolution in pediatric diagnostic and surgical techniques has resulted in a significant Academic Editor: Juan Gómez impact on increasing survival and reducing mortality in children with congenital heart Received: 14 November 2022 disease (CHD) [1,2]. Newborns with tetralogy of Fallot or transposition of the great arteries Accepted: 9 December 2022 have reached adulthood with a good quality of life without relevant incidents [3]. Published: 15 December 2022 Aging is associated with a decline in aerobic capacity (AC) and exercise performance Publisher’s Note: MDPI stays neutral (EP). This is a physiological phenomenon. Adults with CHD (ACHD) often overestimate with regard to jurisdictional claims in their physical capabilities and under-report limitations [4]. The decline in AC may occur published maps and institutional affil- imperceptibly over many years and will be influenced by (1) type of CHD, (2) activity iations. lifestyle during adolescence and adulthood and (3) body weight control [2]. Müller and colleagues [5] suggested that the only way to detect a progressive change in AC is serial exercise testing. In this case, the most recognized methods to exercise testing are the six minute walk test (6MWT) and the cardiopulmonary exercise testing (CPET). The Copyright: © 2022 by the authors. 6MWK is a simple and inexpensive test that provides information about AC based on the Licensee MDPI, Basel, Switzerland. distance walked and the vital signs during the test. On the other hand, the CPET is a more This article is an open access article complex method that provides AC information based on physiological and cardiologic distributed under the terms and parameters during a maximum exercise test [6]. conditions of the Creative Commons One of the objectives of follow-up using consecutive CPET is to assess how much Attribution (CC BY) license (https:// decline occurs in AC measured by VO2peak . creativecommons.org/licenses/by/ 4.0/). Life 2022, 12, 2118. https://doi.org/10.3390/life12122118 https://www.mdpi.com/journal/life Life 2022, 12, 2118 2 of 12 The purpose of this study is to describe our experience with ACHD attending a CPET department and study their evolution of AC [VO2peak ], EP [duration of exercise time, velocity and percentage of grade], and body weight changes. 2. Materials and Methods 2.1. Study Design and Participants We retrospectively reviewed all CPET studies performed in ACHD population be- tween February 2010 and March 2021 in two institutions. Data were obtained by the ACHD unit of Vall d’Hebron Hospital, and at the Santa Creu i Sant Pau Hospital. The inclusion criteria were patients older than 16 years old with CHD who had two or more consecutive CPET separated by at least 1 year. Initially, a total of 151 patients were included. However, 24 of them were excluded based on the following exclusion criteria described below. Six patients were younger than 16 years at first CPET; nine patients had a peacemaker implant that limited heart rate during exercise (eight patients had stimulation mode in DDD and one in VVI); three patients who had residual heart lesions but their initial diagnosis was not a CHD (e.g., rheumatic aortic valve disease); four patients that stopped exercising at the first or the second CPET before reaching their cardiovascular limit, defined as respiratory exchange ratio at peak exercise < 1.15 or heart rate at peak exercise < 85% of the predicted [7,8]; one patient with a severe eating disorder (bulimia) and one patient who had interrupted CPET due to arterial hypertension on effort. Finally, a total of 127 patients were included and provided informed consent. According to AHA/ACC guidelines [2], patients were classified depending on their CHD severity. (1) Moderate (e.g., biventricular repairs including tetralogy of Fallot, atri- oventricular canal defects, and significant valvular issues) and (2) Complex (e.g., patients with single-ventricle physiology, transposition of the great arteries, pulmonary atresia with or without ventricular septal defect, as well as cyanotic lesions) [2]. An expert cardiologist performed this classification without direct relationship with the participants, and without knowledge of the CPET results, to avoid expectation and maintain a blind classification. The study protocol was approved by the FPCEE—Blanquerna institutional research board (protocol nº1718005D) and follows the Helsinki guidelines for ethical behavior [9]. 2.2. Instruments and Procedure 2.2.1. Anthropometric Measurements Height was measured to the nearest 0.1 cm using a stadiometer (Seca 225, Seca, Hamburg, Germany). Weight was measured to the nearest 0.1 kg on a digital scale (Seca 861, Hamburg, Germany) with the subject wearing lightweight clothing and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in squared meters (kg/m2 ) [10]. As recommended by the WHO [11], patients were classified based on BMI as underweight (<18.5 kg/m2 ), normal weight (18.5–24.9 kg/m2 ), overweight (≥25–29.9 kg/m2 ), and obese (≥30 kg/m2 ). 2.2.2. Cardiopulmonary Exercise Testing (CPET) All tests were conducted during the afternoon at a room temperature of 21–22 ◦ C and relative physical humidity between 55 and 65%. The CPET was performed on a treadmill (Schiller® MTM–1500 MED) using a progressive protocol. The participants started walking at 3 km/h for two minutes, after which the speed increased 0.3 km/h and 1.4% grade every minute to a maximum of 12% until exhaustion of participants. Participants were asked every 2/3 min about new appearance of symptoms (such as dyspnea, angina, general discomfort or nausea), and were verbally encouraged to push themselves [12]. Heart rate was obtained using a 12-lead electrocardiogram (Schiller® Cardiovit CS– 200) and blood pressure was measured using a sphygmomanometer (Sphygmomanometer Life 2022, 12, 2118 3 of 12 Riester® model) at rest, at the end of each stage, at peak exercise, and during recovery (at the first, third and fifth minute after finishing the exercise). Physiological parameters of CPET as relative VO2peak (mL/kg/min) and VE/VCO2 slope, were obtained breath-by-breath with an automatic gas analysis system (Ganshorn® Power–cube). The automatic system calculated this parameter based on the Fick method for the estimation of cardiac output from the uptake VO2 and the arterial mixed venous O2 [13]. The expected VO2peak (mL/kg/min) for men and women was obtained with the auto- matic gas analysis system (Ganshorn® Power–cube). The system calculated this parameter based on the equation published by Wassermann et al. [13], considering various influencing factors, including weight (measured and expected), mode of exercise (treadmill) and sex. We compared the VO2peak with the expected VO2peak through a percentage of the difference between the observed and the expected. 2.2.3. Echocardiographic Doppler For each patient, we collected data from the echocardiographic study closest to the date of the CPET period 1 and period 2. This data was collected offline from EchoPAC V.201, GE Healthcare. Echocardiography included left or systemic ventricular ejection fraction (EF). The ventricular ejection fraction, in single ventricle physiology (patients with Fontan), was collected by magnetic resonance imaging, according to cardiological recommendations. 2.2.4. International Physical Activity Questionnaire (IPAQ) The IPAQ was applied to 183 participants; 39 were in a subgroup of patients for whom we obtained prior CPET data. In this subgroup of 39 participants, we assessed their physical activity (PA) at follow-up. The IPAQ short form [14] was used to assess PA levels within the last seven days. The questionnaire can obtain the objective measure equivalent to the energy spent in PA (metabolic equivalent task MET-min/week) reported. The IPAQ includes three questions related to vigorous, moderate and light activity. According to the WHO, acceptable values for adults are above 600 MET-min/week [15]. The IPAQ shows acceptable reliability and validity and it is a valid measurement tool for assessing PA levels in individuals with CHD [16]. 2.2.5. Statistical Analysis Descriptive statistics were calculated for all variables. Continuous variables were expressed as mean and standard deviation (SD) or median (interquartile range) when variables were not normally distributed. Categorical variables were described as fre- quency and percentage. Normal distribution of variables as change in VO2peak , change in body weight and change in EF, was tested by a Kolmogorov–Smirnov test, in addition to visual inspection. Two-way analysis of variance (ANOVA) was used to compare continuous variables between baseline and follow-up in moderate and complex CHD severity, adjusting for sex (men/women) and age of the participants. Associations of changes in HRpeak and follow-up medication; PA (only at follow-up) and VO2peak were assessed using Pearson correlation. Statistical analysis was performed with SPSS version 26 for Windows (IBM SPSS Inc., Armonk, New York, NY, USA). Differences were considered statistically significant if p-values ≤ 0.05. 3. Results Overall, 127 participants were included in the current analysis. The severity of congen- ital heart disease distribution was 59.0% moderate and 41.0% complex (Table 1). The most common diagnosis was transposition of the great arteries, repaired with an atrial switch procedure (seening or mustard repairs) (38.1%) followed by tetralogy of Fallot (31.8%) and Life 2022, 12, 2118 4 of 12 pulmonary valve stenosis (19.1%). The complete description of all diagnostic groups is available in Table 2. Table 1. Distribution of participants by Severity class * (n = 127). Anatomic Functional N % 2A 5 0.8 2B 6 4.7 Moderate (n = 75) 2C 63 49.6 2D 1 0.8 3A 3 2.4 Complex (n = 52) 3B 14 11.0 3C 35 27.6 * Severity class by ACC guidelines [2]. Table 2. Distribution of cases by diagnostic group (n = 127). Diagnostic N % Tetralogy of Fallot 25 31.8 Transposition of the great arteries 30 38.1 Pulmonary valve stenosis 15 19.1 Univentricular heart 13 16.5 Aortic stenosis 12 15.2 Atrioventricular canal defect 7 8.9 Ebstein’s anomaly 7 8.9 Ventricular septal defect 4 5.1 Atrial septal defect 3 3.8 Scimitar syndrome 2 2.5 Pulmonary atresia 3 3.8 Miscellaneous * 6 7.6 * Truncus arteriosus (1); Coronary anomaly (1); Tricuspid dysplasia (1); Patent ductus arteriosus (1); Multiple diagnosis (1); Mitral valve cleft (1). The mean follow-up duration between baseline and final CPET was 4.5 (2.0) years. The median age of the study group was 33.8 years and 57.5% of participants were female (Table 3). At baseline, participants with moderate CHD were significantly older than participants with complex CHD (35.7 [IQR 33.0–38.4] vs. 31.0 [IQR 28.4 × 33.7] years; p = 0.02). At baseline, 50% of participants were in the New York Heart Association (NYHA) functional class I and 50% were in class II. At follow-up, 33.3% of participants were in class I and 84.6% in NYHA class II. At baseline, eight participants had AF/flutter; two of them went through ablation before the first CPET. At follow-up, nine participants had AF/flutter; four of them were the same participants with AF/flutter at baseline (none had ablation recurring). Regarding the new cases of AF/flutter at follow-up, one out of five participants went through ablation between the first and second CPET. All participants had controlled AF/flutter with no impact on the physiological parameters of CPET. Life 2022, 12, 2118 5 of 12 Table 3. Baseline characteristics of CHD participants. Moderate n = 75 Complex n = 52 Total n = 127 Variable Baseline Follow-Up Change Baseline Follow-Up Change Baseline Follow-Up Change Gender (% Female) 61.8% 50.0% 57.5% Age (years) 35.7 (11.7) 40.5 (11.6) 4.7 (1.9) 31.1 (9.5) 35.6 (10.0) 4.5 (2.3) 33.8 (11.1) 38.5 (12.2) 4.6 (2.1) a Height (cm) 167.0 (0.1) 167.0 (0.1) - 165.0 (0.1) 165.0 (0.1) - 166.0 (0.1) 166.0 (0.1) Weight (kg) 66.1 (13.1) 67.4 (13.2) 1.2 (5.9) 62.8 (12.2) 64.8 (13.3) 2.0 (4.1) 64.8 (12.8) 66.3 (23.3) 1.5 (18.0) b BMI (kg/m2 ) 23.5 (3.6) 23.94 (3.8) 0.4 (1.8) 22.8 (3.5) 23.4 (3.8) 0.6 (1.5) 23.2 (3.6) 23.7 (3.8) 0.5 (3.7) b Clinical Data % Ejection fraction 63.5 (9.2) 59.7 (7.1) −3.7 (7.8) 50.1 (15.4) 47.6 (12.6) −3.0 (9.8) 59.6 (12.8) 55.2 (11.1) −3.5 (8.2) a,b Beta-bloquer n (%) 8 (6.3%) 16 (12.6%) 8 8 (6.3%) 16 (12.6%) 8 16.0 (12.6%) 32.0 (25.2) 16 b ACE/Diuretics n (%) 5 (3.9%) 11 (8.7%) 6 5 (3.9%) 8 (6.3%) 3 10.0 (7.9%) 19.0 (15.0) 9b CPET data VE/VCO2 slope 26.0 (5.9) 27.2 (4.7) 1.2 (0.6) 28.1 (7.3) 30.2 (8.4) 2.1 (0.7) 26.9 (6.6) 28.5 (6.7) 1.6 (4.9) a,b % VO2 predicted 87.6 (21.4) 85.8 (19.9) −1.8(16.8) 76.1 (16.4) 70.0 (18.5) −6.0 (13.3) 82.9 (20.3) 79.3 (20.8) −3.5 (15.7) a,b VO2 absolute (L/min) 1.8 (0.6) 1.9 (0.7) 0.01 (0.03) 1.7 (0.5) 1.6 (0.5) −0.1 (0.3) 1.8 (0.6) 1.8 (0.6) −0.03 (0.36) a VO2peak (mL/kg/min) 28.3 (8.4) 27.8 (8.4) −0.5 (5.6) 27.2 (6.5) 24.8 (6.7) −2.3 (4.7) 27.8 (27.7) 26.6 (7.8) −1.3 (5.3) b Peak O2 pulse 11.4 (3.8) 11.5 (3.4) 0.1 (2.5) 11.1 (3.7) 10.6 (3.7) −0.5 (1.9) 11.2 (3.7) 11.1 (3.6) −0.1(2.8) HRpeak (bpm) 163.0 (19.6) 161.9 (21.2) −1.1 (16.4) 156.3 (22.7) 154.2 (23.4) −2.1 (15.9) 160.3 (21.1) 158.8 (22.3) −1.5(16.0) a Time exercise (minutes) 13.0 (3.4) 12.6 (2.7)) −0.4 (2.8) 12.6 (2.8) 12.4 (2.4) −0.2 (1.9) 12.8 (3.2) 12.6 (2.7) −0.3 (2.5) Percentage slope (%) 11.4 (1.5) 11.6 (1.2) 0.2 (1.5) 11.6 (1.0) 11.8 (0.7) 0.2 (0.9) 11.5 (1.3) 11.7 (1.0) 0.2 (1.3) Maximal Velocity (km/h) 6.3 (1.1) 6.2 (0.9) −0.1 (0.8) 6.2 (0.9) 6.0 (0.9) −0.2 (0.6) 6.2 (1.0) 6.1 (0.9) −0.1 (0.7) Note: BMI, body mass index. Values are presented as mean and standard deviation (SD). a Comparing between severity CHD groups p < 0.05. b Comparing baseline values with follow-up by a post-hoc comparison, two-way ANOVA p < 0.001 except for VO2peak p = 0.003. impact on the physiological parameters of CPET. 3.1. Longitudinal Changes in the Different Groups of CHD 3.1.1. The VO2peak Life 2022, 12, 2118 6 of 12 There was a significant decline in the VO2peak from 27.8 (7.7) mL/kg/min to 26.6 (7 mL/kg/min at follow-up. This decrease converted to percent VO2 predicted was fro 82.9% (20.3%) to 79.3% (20.8%) at follow-up. 3.1. Longitudinal Changes in the Different Groups of CHD The decline in VO2peak is statistically significant in both severity CHD groups duri 3.1.1. The VO2peak follow-up; p = 0.003 (Table 3). The moderate group had a lower decline than the comp There was a significant decline in the VO2peak from 27.8 (7.7) mL/kg/min to 26.6 group (−0.5 (5.6) mL/kg/min vs. −2.3 (4.7) mL/kg/min, respectively). (7.8) mL/kg/min at follow-up. This decrease converted to percent VO2 predicted was from In order to 82.9% (20.3%) to understand 79.3% (20.8%)the evolution of VO2peak, we investigated how the VO2peak w at follow-up. changed The during decline infollow-up. VO2peak is A total of 56.5% statistically of participants significant in both severityhadCHDa decreased VO2peak, 33. groups during follow-up; p of participants increased and 9.6% of participants maintained the VO2peak at follow-up. = 0.003 (Table 3). The moderate group had a lower decline than the complex groupThe (−different 0.5 (5.6) mL/kg/min vs. −2.3 (4.7) ranges of decreased VOmL/kg/min, 2peak were: (a)respectively). between 1 and 4 mL/kg/min: 33. In order to understand the evolution of VO2peak , we investigated how the VO2peak was of participants; (b) between 5 and 10 mL/kg/min: 18.8% of participants and (c) > changed during follow-up. A total of 56.5% of participants had a decreased VO2peak , 33.9% mL/kg/min: of participants 4.7% of participants. increased The different and 9.6% of participants rangesthe maintained of VOincreased VO2peak were (a) 2peak at follow-up. tweenThe 1 and 4 mL/kg/min: 21.3% of participants and (b) >5 mL/kg/min: different ranges of decreased VO2peak were: (a) between 1 and 4 mL/kg/min: 12.6% of part pants. 33.0% of participants; (b) between 5 and 10 mL/kg/min: 18.8% of participants and (c) >10 Among mL/kg/min: 4.7% of participants. the participants who increased The more different thanranges of increased 5 mL/kg/min of VO VO2peak 2peak, seven were (a) between 1 and 4 mL/kg/min: 21.3% of participants them began to practice PA; seven had a replaced pulmonary valve interventionand (b) >5 mL/kg/min: 12.6% and t of participants. remaining two had an aortic valve replacement intervention between two CPETs. Among the participants who increased more than 5 mL/kg/min of VO2peak , seven of them There beganwere no significant to practice PA; sevendifferences had a replaced in EP (time exercise, pulmonary percentage valve intervention slope and the and m imal velocity) between baseline and follow-up or between remaining two had an aortic valve replacement intervention between two CPETs. severities CHD groups (Ta 3). MeanThere exercise were no time was 12.8 significant min, theinmean differences percentage EP (time exercise,slope was 11.4% percentage slope and and the me maximal velocity) between baseline maximal velocity was 6.2 km/h at baseline. and follow-up or between severities CHD groups (Table In 3). Mean exercise a subgroup of 39timeparticipants was 12.8 min,withthe mean percentage measures of PA slope by was 11.4% IPAQ, theand the median PA mean maximal velocity was 6.2 km/h at baseline. ports as assessed by IPAQ at follow-up were 2079.0 (IQR 2772.0) MET-min/week, oscill In a subgroup of 39 participants with measures of PA by IPAQ, the median PA reports ing betweenby0 IPAQ as assessed and 9564.0 MET-min/week at follow-up (Table were 2079.0 (IQR 3). From 2772.0) 39 participants MET-min/week, that answer oscillating the IPAQ0questionnaire, between 13 (33.3%) reported and 9564.0 MET-min/week (Table 3). health-enhancing From 39 participantsPA, that19 (48.7%) report answered minimally active, and 713 the IPAQ questionnaire, (17.9%) (33.3%)reported reported inactivity. However, health-enhancing PA, 19the PA data (48.7%) have not be reported minimally active, and 7 (17.9%) reported inactivity. However, the PA sufficient to study the evolution in the statistical analysis model. The Pearson correla data have not been sufficient to study the evolution in the statistical analysis model. The Pearson correlates showed a positive trend between PA (MET-min/week) and AC at the follow-up asse showed a positive trend between PA (MET-min/week) and AC at the follow-up assessment ment (p = 0.06) (Figure 1). (p = 0.06) (Figure 1). Figure 1. Aerobic capacity (VO2peak ) depending on physical activity (MET-min/week) assessed by IPAQ in the follow-up. 3.1.2. Maximum Heart Rate (HRpeak ) in Exercise Mean HRpeak was 160.3 beats per minute (bpm) at baseline and 158.8 bpm at follow-up. There is a significant difference in HRpeak between CHD groups (p = 0.04). The moderate 3.1.2. Maximum Heart Rate (HRpeak) in Exercise Mean HRpeak was 160.3 beats per minute (bpm) at baseline and 158.8 bpm at follow- up. There is a significant difference in HRpeak between CHD groups (p = 0.04). The moder- Life 2022, 12, 2118 ate CHD group achieved an HRpeak higher than the complex CHD group in both periods 7 of 12 (Table 3). However, no significant differences were found between periods. The reduction in the HRpeak in both CHD groups has been associated with the in- creased CHDuse of beta-blocker group achieved an and HR diuretic medication peak higher than theduring the follow-up; complex CHD group p =in 0.04 (Figure both periods 2). At baseline, (Table 16 (12.5%) 3). However, participants no significant used a beta—Bisoprolol differences were found between (n = 4), Atenolol (n = 3), periods. Carvedilol The(nreduction = 3), othersinthat thecombined HRpeak in a beta-blocker both CHD groupswith anhasantiarrhythmic (n = 6);with been associated and the 10 (7.8%) participants used an Angiotensin-converting enzyme (ACE)/diuretics—Enalap- increased use of beta-blocker and diuretic medication during the follow-up; p = 0.04 ril (n = 9), others (Figure 2). At (n = 2). During baseline, follow-up, 16 (12.5%) there was participants used ana increase resulting (n beta—Bisoprolol in = 324), (25.1%) Atenolol participants taking beta-blocker—Bisoprolol (n = 3), Carvedilol (n = 13), aCarvedilol (n = 3), others that combined beta-blocker(n =with 5), Atenolol (n = 4), an antiarrhythmic Amiodarone (n = 6); and(n = 3), 10 or othersparticipants (7.8%) that combined a beta-blocker used with an antiarrhythmic an Angiotensin-converting enzyme (n=(ACE)/ 7); anddiuretics—Enalapril 19 (14.9%) participants (n used = 9), ACE/diuretics—Enalapril others (n = 2). During follow-up, there (n (n = 9), Losartan was anothers = 3), increase (n =resulting 7). in 32 (25.1%) participants taking beta-blocker—Bisoprolol (n = 13), Carvedilol (n = 5), Atenolol (n = 4), Amiodarone (n = 3), or others that combined a beta-blocker with an antiarrhythmic (n = 7); and 19 (14.9%) participants used ACE/diuretics—Enalapril (n = 9), Losartan (n = 3), others (n = 7). Figure 2. Evolution in HRpeak according to the use of medication. Figure 2. Evolution in HRpeak according to the use of medication. 3.1.3. VE/VCO2 Slope 3.1.3. VE/VCO 2 Slope The mean of the VE/VCO2 slope was 26.9 (6.6) at baseline and 28.5 (6.7) at follow-up. There was a of The mean significant the VE/VCOincrease in was 2 slope VE/VCO 2 slope 26.9 (6.6) for both and at baseline CHD28.5groups. The (6.7) at mean of the follow-up. increase There was awas 1.57 (4.9) significant at follow-up. increase in VE/VCO2 slope for both CHD groups. The mean of the increaseThe wascomplex 1.57 (4.9)CHD group had a significantly higher mean VE/VCO2 than the moderate at follow-up. CHD group in CHD The complex both periods group had(Table 3). a significantly higher mean VE/VCO2 than the moder- There were five participants ate CHD group in both periods (Table 3). with a VE/VCO 2 higher than 40 (range 42.1 to 62.7) atThere baseline. Among them, two participants decreased were five participants with a VE/VCO2 higher than VE/VCO 2 to 42.1 40 (range normal values to 62.7) at at follow-up and three participants with a univentricular baseline. Among them, two participants decreased VE/VCO2 to normal heart (VO values at follow-and 2peak between 12.6 up 18.9 and mL/kg/min and %V0 three participants with2 predicted below 40%) a univentricular heartwere referred (VO2peak for cardiac between 12.6 andtransplant 18.9 during follow-up. mL/kg/min and %V02 predicted below 40%) were referred for cardiac transplant during follow-up. 3.1.4. Ejection Fraction (EF) The percentage of participants with reduced EF (<50%) was lower in the moderate group than the complex group in both periods (2.8% of participants vs. 53.3%, respectively at baseline; and 9.3% of participants vs. 55.6% at follow-up). The mean percentage of EF in the moderate CHD group was significantly higher than in the complex CHD group in both periods (64% vs. 50%, respectively, at baseline and 60% vs. 48% at follow-up; p < 0.001). There was a significant decrease in EF in both severity CHD groups during follow-up. The mean decrease in EF at follow-up was significantly higher in the moderate CHD group than the complex CHD group (−3.7% (7.7) vs. −3.0% (9.7), respectively); p < 0.001 (Table 3). A total of 60.8% of participants decreased their EF at follow-up, 33.7% of participants increased and 5.5% maintained the same percentage of EF. Life 2022, 12, 2118 8 of 12 When we compared EF by severity, we observed that a higher baseline EF was associ- ated with a greater decrease in EF during the follow-up period. However, the reduction in EF has not been associated with the decrease in AC (p = 0.96). 3.2. Longitudinal Association between Body WEIGHT Changes and Aerobic Capacity At baseline, the majority of participants had normal body weight (59.4%), while 29.9% of participants were overweight, 7.8% were underweight and 2.3% were classified as obese (Table 3). The mean amount of body weight change during follow-up was an increase of 1.5 (5.3) kg., a total of 58.3% of participants increased their body weight, 25.2% decreased and 16.5% maintained their body weight during follow-up. The two-way ANOVA showed that the body weight increase is significant during follow-up (p = 0.001) and it is independent of the severity (p = 0.41). In Figure 3, we observed the changes in body weight and their relation with the Life 2022, 12, x FOR PEER REVIEW VO 2peak at follow-up. The most common change was an increase between 1 and 59 kg at of 13 follow-up (42.2% of the participants) followed by the maintenance on body weight (16.5% of the participants) and a decrease between 1 and 5 kg (16.5% of participants). Figure 3. Aerobic Capacity (VO2peak ) change depending on body weight change. Figure 3. Aerobiccorrelation Pearson’s Capacity (VO 2peak) change depending on body weight change. revealed the small negative association between body weight and increased AC (measured by VO2peak ) in both CHD groups, regardless of gender or age. 4. Discussion Despite this correlation, in general there was only a trend (p = 0.15). The tendency is more CPET evident is acomplex in the method to assess CHD groupAC(ppermitting physicians = 0.07) than to take the moderate objective CHD groupmedical deci- (p = 0.57). sions and give specific recommendations about physical exercise. 4. Discussion This observational study assessing two different CPET results from a sample of 127 CHDCPET is ahas patients method giventousassess a wide ACrange permitting physicians of information to take about objective changes in AC medical duringdeci- fol- sions and low-up in give specific recommendations about physical exercise. this population. Thisaim The observational of this studystudy assessing was to describetwoour different experience CPET with results ACHD from a sample attending a CPET of 127 CHD patients department has given and study us aevolution their AC wide range(VOof information 2peak about ), EP (duration of changes in ACvelocity exercise time, during follow-up and in thisofpopulation. percentage grade), and assess if the body weight changes could worsen the AC of The adults aim with of this study moderate was to describe and complex CHD. our experience with ACHD attending a CPET department and study The current studytheir AC evolution showed (VO2peak a reduction in AC ), EP in(duration moderateofandexercise time, severity complex velocity groups during the follow-up. These findings are in accordance with the longitudinal AC and percentage of grade), and assess if the body weight changes could worsen the studyof adults with moderate and complex CHD. of Müller, et al. [5]. These authors described a progressive but slow decline in VO2peak −1.75 (4.42) ml/kg/min in 2.5 years. In our study, this decline was −1.27 (5.33) ml/kg/min in 4.5 years. The slow reduction in VO2peak observed in our cohort could be interpreted as clinical stabilization in the functional impact of heart disease due to the short follow-up time. Aerobic capacity is correlated with exercise capacity. In this context, the VO2peak ob- Life 2022, 12, 2118 9 of 12 The current study showed a reduction in AC in moderate and complex severity groups during the follow-up. These findings are in accordance with the longitudinal study of Müller, et al. [5]. These authors described a progressive but slow decline in VO2peak −1.75 (4.42) mL/kg/min in 2.5 years. In our study, this decline was −1.27 (5.33) mL/kg/min in 4.5 years. The slow reduction in VO2peak observed in our cohort could be inter- preted as clinical stabilization in the functional impact of heart disease due to the short follow-up time. Aerobic capacity is correlated with exercise capacity. In this context, the VO2peak obtained by CPET is the most objective clinical parameter of AC assessment and estimating exercise capacity. A patient is considered to reach their VO2peak when they reach exhaus- tion and cannot continue with physical exercise. The physiological mechanism to reach exhaustion is double; it depends on the central factor (e.g., heart rate) and the peripheral factor (characteristics of the skeletal muscle: body weight and exercise adaptations). Based on the physiological mechanism, there are some arguments that could explain the slight reduction in VO2peak . One of them is related to a central factor and it refers to the maintenance of the HRpeak reached during exercise. Because of a reduced ejection fraction that some CHD patients have, treatment with beta-blockers is relatively frequent. In fact, we observed a greater number of patients taking beta-blockers at second CPET. This therapeutic measure could favorably contribute to the VO2peak response at follow-up. Moving the peripheral factor, an important variable that influences cardiac output is body weight. Absolute VO2 (L/min) reduction at follow-up was not significant in our sample. However, for VO2peak , the difference between periods is relevant. This occurs because body weight is the denominator in the mathematical equation for obtaining relative VO2peak [VO2 (L/min)/body weight (kg)] [13]. For example, a patient weighing 60 kg with an initial absolute VO2 consumption of 1800 L/min in the first test will have a consumption of VO2peak relative 30 mL/kg/min (1800/60). If this patient in the second test reaches the same absolute consumption of 1800 L/min but has increased his body weight to 65 kg, his VO2peak relative consumption will be lower, reaching 27 mL/kg/min (1800/65). In this way, VO2peak consumption will be lower even without a deterioration in cardiac function. This mathematical explanation of the equation is evident in the inverse correlation that we found between body weight and VO2peak in our cohort. Nevertheless, the reduction in VO2peak at follow-up observed in our cohort was independent of body weight changes. We believe that this result could be explained by the fact that the absolute weight gain was not very high (range between 1–5 kg in 4.5 years). Brida et al. [17], in a study with more than 3000 ACHD patients, suggested that temporary changes in body weight could provide prognostic information, especially when associated with decreased physical capacity. The authors also concluded that symptomatic ACHD patients (NYHA >= 2) may fare better when maintaining a higher BMI (between 24–30 kg/m2 ). We believe that even with absolute weight gain, the maintenance of a healthy BMI range may have contributed to the low VO2peak reduction in our cohort. Willinger et al. [18] published a review including 6657 ACHD patients and they observed an overweight prevalence in a range from 22 to 53%, while obesity was reported in a range between 7% and 26%. In our cohort, only 29.9% were overweight and 2.3% were obese in the baseline. The changes in body weight have been significant during follow-up. However, the average BMI has remained within normal values, keeping the majority of the sample (60.6% of participants) with normal weight during follow-up. Some studies have described that patients with CHD are more likely to be involved in their health care and control of cardiovascular risk factors [19,20]. In this way, we highlight the importance of health education and the promotion of an active lifestyle, with the aim that each patient can understand how the peripheral factor can affect their physical capacity even when the body weight gain is only between 1 and 5 kg. We also assessed the relationship between EF and AC. In our sample, the decline in EF has been shown to be significant during follow-up. When we compared EF by CHD severity, we observed that a higher baseline EF was associated with a greater decrease in Life 2022, 12, 2118 10 of 12 EF during the follow-up period. However, the reduction in EF has not been associated with the decrease in AC. This finding is in accordance with Cuypers J. et al. [21]. The authors presented results of EF and AC in a long-term follow-up study with a cohort of TGA participants evaluated systematically every 10 years starting from birth, for nearly 40 years. The study showed a progressive decrease in EF in the last 10 years of follow-up (between 30-40 years old); however, AC remained stable. The VE/VCO2 slope is another CPET systematically evaluated in our cohort of patients. It describes the relationship between ventilation and CO2 production, indicating the state of ventilatory efficiency [12]. Values above 35 accompanied by a low VO2peak can result in poor prognosis in ACHD [22]. In our study, a progressive increase in the VE/VCO2 slope occurred in association with VO2peak decrease. This observation underlines the potential importance of studying the mechanisms responsible for this clinical parameter. Contrary to expectations, this study did not find a significant difference in the EP between baseline and follow-up period. Muller et al. [5] presented EP results which were similar to our study but with EP measured by the load peak (watts). There were no signifi- cant differences in EP between baseline and a follow-up period of 2.5 years. Nevertheless, when the peak considered the patient’s body weight, they observed a decreased mean of −0.13 watts.kg between same periods. These findings are in accordance with our study and highlight the importance of controlling peripheral factors such as body weight in the assessment of AC and EP. One reason for the favorable results of EP in our study could be that our CPET department is extremely engaged in PA and sports participation promotion. After first CPET, all patients receive advice about what kind of physical exercise is safe and useful. This attitude could have influenced the activity lifestyle of participants during follow-up. Unfortunately, exercise participation data has not been provided in the clinical data of all participants. Nerveless, we could include a subgroup of 39 participants with PA assessed by an IPAQ at follow-up. In this study, we cannot conclude that there is a direct relationship between PA and AC. However, our findings are consistent with our previous study [23] and some current studies reporting a positive association between PA and AC, emphasizing that increasing PA practice can improve AC in CHD population [4,24–26]. Another explanation is very speculative and it could be related to the management of CPET protocol. Patients were instructed not to hold onto the treadmill safety bar, but in some cases they did, and a possible explanation could be patients’ lack of balance or lack of experience in CPET on a treadmill. In this case, it would be relevant to record information about the position of the hands during the test and, if holding on to the safety bar, consider it in the final assessment of peak VO2 consumption. The limitations of this study are inherent and common to all retrospective studies. We emphasize the lack of PA data in the clinical database. We believe that physical activity data, as well as interventions (events, ablations and interventional catheterization), should be included in the analysis model to determine whether the reduction in AC is due to physical deterioration and/or evolution of heart disease. Despite this, the strength of our study is that, regardless of the unavailable variables, studying the trend of the gold standard AC parameter (VO2peak ) can predict the prognosis of the CHD population [22,27–30]. Nevertheless, these data must be interpreted with caution due to the brief (4.5 years) period of follow-up reported in our study. Moodie D. [31] suggests that proper follow-up needs to find and track CHD patients over 30 to 50 years. In this line, future research with a longer follow-up is needed to obtain consistent results about AC evolution in ACHD population. 5. Conclusions AC in ACHD patients declined during follow-up. This decline was not related to body weight change and the decrease in the EF. Despite this, the HRpeak and the EP (duration of exercise time, velocity and percentage of grade) were maintained without a deterioration over time. These results suggest a sign of favorable functional cardiac evolution of the Life 2022, 12, 2118 11 of 12 ACHD population. More research is needed, including the level of physical activity of ACHD, in addition to all intervention procedures and events occurring during the follow-up period, to study the contribution of each factor to AC reduction. Author Contributions: Conceptualization, K.F. and R.S.-G.; methodology, K.F. and R.S.-G.; formal analysis, I.G.; data curation, M.D., B.C.-P., K.F. and M.P.; resources M.D. and L.D.-S.; writing—original draft preparation, K.F. and R.S.-G.; writing—review and editing, M.G.-B., G.R.O., B.C.-P. and I.G.; supervision, G.R.O. and R.S.-G. All authors have read and agreed to the published version of the manuscript. Funding: This research was funded by SUR of DEC Generalitat de Catalunya and European Union, PhD grant number 2020FI_B2_00128. The funder had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Institutional Review Board Statement: The study was conducted in accordance with the Declara- tion of Helsinki, and approved by the FPCEE—Blanquerna institutional research board (protocol nº1718005D). Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. Data Availability Statement: Not applicable. Acknowledgments: We would like to thank the Cors Units Foundation for the support in all the cardiopulmonary exercise testing resources. Conflicts of Interest: The authors declare no conflict of interest. References 1. GBD 2017 Congenital Heart Disease Collaborators. Global, Regional, and National Burden of Congenital Heart Disease, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet Child Adolesc. Health 2020, 4, 185–200. [CrossRef] [PubMed] 2. Stout, K.K.; Daniels, C.J.; Aboulhosn, J.A.; Bozkurt, B.; Broberg, C.S.; Colman, J.M.; Crumb, S.R.; Dearani, J.A.; Fuller, S.; Gurvitz, M.; et al. 2018 AHA/ACC Guideline for the Management of Adults with Congenital Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019, 139, e698–e800. [CrossRef] [PubMed] 3. Serra-Grima, R.; Ferri, K.; Rissech, M. Study of Physically Active Children with Congenital Heart Disease. In Recent Developments in Medicine and Medical Research; B P intenational: London, UK, 2021; Volume 5, pp. 139–145. 4. Müller, J.; Hess, J.; Hager, A. Daily Physical Activity in Adults with Congenital Heart Disease Is Positively Correlated with Exercise Capacity but Not with Quality of Life. Clin. Res. Cardiol. 2012, 10, 55–61. [CrossRef] [PubMed] 5. Müller, J.; Ewert, P.; Hager, A. Only Slow Decline in Exercise Capacity in the Natural History of Patients with Congenital Heart Disease: A Longitudinal Study in 522 Patients. Eur. J. Prev. Cardiol. 2015, 22, 113–118. [CrossRef] [PubMed] 6. Kehmeier, E.S.; Sommer, M.H.; Galonska, A.; Zeus, T.; Verde, P.; Kelm, M. Diagnostic value of the six-minute walk test (6MWT) in grown-up congenital heart disease (GUCH): Comparison with clinical status and functional exercise capacity. Int. J. Cardiol. 2016, 203, 90–97. [CrossRef] 7. Kipps, A.K.; Graham, D.A.; Lewis, E.; Marx, G.R.; Banka, P.; Rhodes, J. Natural History of Exercise Function in Patients with Ebstein Anomaly: A Serial Study. Am. Heart J. 2012, 163, 486–491. [CrossRef] 8. Fernandes, S.M.; McElhinney, D.B.; Khairy, P.; Graham, D.A.; Landzberg, M.J.; Rhodes, J. Serial Cardiopulmonary Exercise Testing in Patients with Previous Fontan Surgery. Pediatr. Cardiol. 2010, 31, 175–180. [CrossRef] 9. World Medical Association WMA. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA 2013, 310, 2191–2194. [CrossRef] 10. Word Health Organization WHO. Obesity: Preventing and Managing the Global Epidemic. WHO Tech. Rep. Ser. 2000, 894, 252. Available online: https://apps.who.int/iris/handle/10665/42330 (accessed on 14 June 2022). 11. Word Health Organization WHO. Obesity and Overweight: Fact Sheet. WHO Media Centre. 2016. Available online: https://www. who.int/news-room/fact-sheets/detail/obesity-and-overweight (accessed on 20 May 2022). 12. Serra-Grima, R. Cardiologia en el Deporte: Revisión de Casos Clínicos Basados en la Evidencia, 3rd ed.; Elsevier: Barcelona, Spain, 2015. 13. Wasserman, K.; Hansen, J.; Sue, D.; Whipp, B.; Casaburi, R. Principles of Exercise Testing and Interpretation, 4th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2004. 14. Craig, C.L.; Marshall, A.L.; Sjöström, M.; Bauman, A.E.; Booth, M.L.; Ainsworth, B.E.; Pratt, M.; Ekelund, U.; Yngve, A.; Sallis, J.F.; et al. International Physical Activity Questionnaire: 12-Country Reliability and Validity. Med. Sci. Sports Exerc. 2003, 35, 1381–1395. [CrossRef] Life 2022, 12, 2118 12 of 12 15. Word Health Organization WHO. WHO Guidelines on Physical Activity and Sedentary Behaviour; World Health Organization: Geneva, Switzerland, 2020. 16. Müller, J.; Amberger, T.; Berg, A.; Goeder, D.; Remmele, J.; Oberhoffer, R.; Ewert, P.; Hager, A. Physical Activity in Adults with Congenital Heart Disease and Associations with Functional Outcomes. Heart 2017, 103, 1117–1121. [CrossRef] [PubMed] 17. Brida, M.; Dimopoulos, K.; Kempny, A.; Liodakis, E.; Alonso-Gonzalez, R.; Swan, L.; Uebing, A.; Baumgartner, H.; Gatzoulis, M.A.; Diller, G.P. Body Mass Index in Adult Congenital Heart Disease. Heart 2017, 103, 1250–1257. [CrossRef] [PubMed] 18. Willinger, L.; Brudy, L.; Meyer, M.; Oberhoffer-fritz, R.; Ewert, P.; Müller, J. Overweight and Obesity in Patients with Congenital Heart Disease: A Systematic Review. Int. J. Environ. Res. Public Health 2021, 18, 9931. [CrossRef] [PubMed] 19. Moons, P.; van Deyk, K.; Dedroog, D.; Troost, E.; Budts, W. Prevalence of Cardiovascular Risk Factors in Adults with Congenital Heart Disease. Eur. J. Cardiovasc. Prev. Rehabil. 2006, 13, 612–616. [CrossRef] [PubMed] 20. Holbein, C.E.; Peugh, J.; Veldtman, G.R.; Apers, S.; Luyckx, K.; Kovacs, A.H.; Thomet, C.; Budts, W.; Enomoto, J.; Sluman, M.A.; et al. Health Behaviours Reported by Adults with Congenital Heart Disease across 15 Countries. Eur. J. Prev. Cardiol. 2020, 27, 1077–1087. [CrossRef] 21. Cuypers, J.A.A.E.; Eindhoven, J.A.; Slager, M.A.; Opi, P.; Utens, E.M.W.J.; Helbing, W.A.; Witsenburg, M.; van den Bosch, A.E.; Ouhlous, M.; van Domburg, R.T.; et al. The Natural and Unnatural History of the Mustard Procedure: Long-Term Outcome up to 40 Years. Eur. Heart J. 2014, 35, 1666–1674. [CrossRef] 22. Kempny, A.; Dimopoulos, K.; Uebing, A.; Moceri, P.; Swan, L.; Gatzoulis, M.A.; Diller, G.P. Reference Values for Exercise Limitations among Adults with Congenital Heart Disease. Relation to Activities of Daily Lifesingle Centre Experience and Review of Published Data. Eur. Heart J. 2012, 33, 1386–1396. [CrossRef] 23. Ferri, K.; Doñate, M.; Parra, M.; Oviedo, G.R.; Guerra-Balic, M.; Rojano-Doñate, L.; Blackburn, N.; Serra-Grima, R. What Is the Relation between Aerobic Capacity and Physical Activity Level in Adults with Congenital Heart Disease? Congenit. Heart Dis. 2021, 16, 585–595. [CrossRef] 24. Meyer, M.; Brudy, L.; García-Cuenllas, L.; Hager, A.; Ewert, P.; Oberhoffer, R.; Müller, J. Current State of Home-Based Exercise Interventions in Patients with Congenital Heart Disease: A Systematic Review. Heart 2020, 106, 333–341. [CrossRef] 25. Sandberg, C.; Pomeroy, J.; Thilén, U.; Gradmark, A.; Wadell, K.; Johansson, B. Habitual Physical Activity in Adults with Congenital Heart Disease Compared with Age- and Sex-Matched Controls. Can. J. Cardiol. 2016, 32, 547–553. [CrossRef] 26. Bay, A.; Dellborg, M.; Berghammer, M.; Sandberg, C.; Engstrom, G.; Moons, P.; Johansson, B. Patient Reported Outcomes Are Associated with Physical Activity Level in adults with Congenital Heart Disease. Int. J. Cardiol. 2017, 243, 174–179. [CrossRef] [PubMed] 27. Bredy, C.; Ministeri, M.; Kempny, A.; Alonso-Gonzalez, R.; Swan, L.; Uebing, A.; Diller, G.-P.; Gatzoulis, M.A.; Dimopoulos, K. New York Heart Association (NYHA) Classification in Adults with Congenital Heart Disease: Relation to Objective Measures of Exercise and Outcome. Eur. Heart J. Qual. Care Clin. Outcomes 2018, 4, 51–58. [CrossRef] 28. Müller, J.; Hager, A.; Diller, G.P.; Derrick, G.; Buys, R.; Dubowy, K.O.; Takken, T.; Orwat, S.; Inuzuka, R.; Vanhees, L.; et al. Peak Oxygen Uptake, Ventilatory Efficiency and QRS-Duration Predict Event Free Survival in Patients Late after Surgical Repair of Tetralogy of Fallot. Int. J. Cardiol. 2015, 196, 158–164. [CrossRef] [PubMed] 29. Diller, G.P.; Dimopoulos, K.; Okonko, D.; Li, W.; Babu-Narayan, S.V.; Broberg, C.S.; Johansson, B.; Bouzas, B.; Mullen, M.J.; Poole-Wilson, P.A.; et al. Exercise Intolerance in Adult Congenital Heart Disease: Comparative Severity, Correlates, and Prognostic Implication. Circulation 2005, 112, 828–835. [CrossRef] [PubMed] 30. Dimopoulos, K.; Okonko, D.O.; Diller, G.P.; Broberg, C.S.; Salukhe, T.V.; Babu-Narayan, S.V.; Li, W.; Uebing, A.; Bayne, S.; Wensel, R.; et al. Abnormal Ventilatory Response to Exercise in Adults with Congenital Heart Disease Relates to Cyanosis and Predicts Survival. Circulation 2006, 113, 2796–2802. [CrossRef] [PubMed] 31. Moodie, D. Long-Term Follow-up Studies in Congenital Heart Disease-How Long Is Long? Congenit. Heart Dis. 2014, 9, 87–88. [CrossRef]